CervoMed to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in September 2025.

The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, from 2:00 to 2:30 PM ET, with both presentation and one-on-one investor meetings. Additionally, CervoMed will participate in Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, 2025, featuring one-on-one investor meetings.

News Market Reaction – CRVO

+5.89%

11 alerts

+5.89% Session close to close

+3.0% Peak Tracked

-9.1% Trough Tracked

$100.76M Market Cap

1.2x Rel. Volume

In the Sep 3 session, CRVO gained 5.89%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.0% during that session. Argus tracked a trough of -9.1% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September:

H.C. Wainwright 27^th Annual Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Presentation Date: Monday, September 8, 2025
Presentation Time: 2:00 – 2:30 PM ET
Webcast: https://journey.ct.events/view/b01e16a4-43fd-41b8-b4c0-2815213f7950

Morgan Stanley’s 23^rd Annual Global Healthcare Conference
Format: 1x1 Investor Meetings
Conference Dates: September 8-10, 2025

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579

FAQ

When is CervoMed (NASDAQ: CRVO) presenting at the H.C. Wainwright Conference?

CervoMed will present on Monday, September 8, 2025, from 2:00 to 2:30 PM ET at the H.C. Wainwright 27th Annual Global Investment Conference.

How can investors access CervoMed's H.C. Wainwright conference presentation?

Investors can access the presentation webcast through https://journey.ct.events/view/b01e16a4-43fd-41b8-b4c0-2815213f7950 or through the Investor section of CervoMed's website.

What type of company is CervoMed (CRVO)?

CervoMed is a clinical stage company focused on developing treatments for age-related neurologic disorders.

Which investor conferences will CervoMed attend in September 2025?

CervoMed will attend the H.C. Wainwright 27th Annual Global Investment Conference and Morgan Stanley's 23rd Annual Global Healthcare Conference in September 2025.